Novartis/Antisoma's ASA404 Stumbles Badly In Phase III Lung Cancer Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis and Antisoma prematurely halted a Phase III study of ASA404 - a potentially first-in-class tumor vascular-disrupting agent - after an interim analysis showed that continuing the trial would be futile. Though lung cancer is a notorious mine field for drug development, the March 29 news still was a big surprise since a similar Phase II trial showed a significant survival benefit in patients treated with the drug
You may also be interested in...
Beyond Gleevec: What's Next For Novartis Oncology?
For Novartis, the targeted chronic myeloid leukemia drug Gleevec (imatinib) has been the backbone of its oncology portfolio. The drug's launch in 2003 catapulted Novartis into a major oncology player, and with revenues for Gleevec now approaching close to $4 billion in sales annually, the drug has evolved from what was considered to be a niche treatment into Novartis' second top-selling drug
Novartis Looks To Bring First-In-Class Vascular Disrupting Agent To Market
Company will move the oncologic into Phase III in non-small cell lung cancer in 2008 under a deal with Antisoma, potentially worth more than $890 million.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011